Key result
Existing VTE risk prediction models, such as the Khorana, PROTECHT, and CONKO scores, showed poor performance in external validations, failing to identify many high-risk lung cancer patients.
Why the study?
Anticoagulation for VTE prophylaxis in ambulatory lung cancer patients carries bleeding risk, and the availability of a reliable VTE predictive model for this population is unclear.
What is the performance of existing VTE risk prediction models in ambulatory patients with lung cancer?
Population
Ambulatory patients with lung cancer
Design
Review
Authors
Loading...
Existing VTE scores should not guide prophylaxis in lung cancer; leaves open need for improved, validated models.
What is the performance of existing VTE risk prediction models in ambulatory patients with lung cancer?
Current VTE risk prediction models perform poorly in ambulatory lung cancer patients, highlighting the need for newly developed and validated models.
Yan et al. (2021) conducted a review in Venous thromboembolism in ambulatory patients with lung cancer. VTE risk prediction models was evaluated. Existing VTE risk prediction models, such as the Khorana, PROTECHT, and CONKO scores, showed poor performance in external validations, failing to identify many high-risk lung cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: